Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Cutaneous Lichen Planus
NCT05188521Phase 2Completed
- Start
- Jan 2022
- Primary completion
- May 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of baricitinib in lichen planus (LP) (2 arms). Primary endpoint: Physician Global Assessment at 16 weeks. Started Jan 2022; status: completed.
02
Drugs
baricitinib
03
Conditions
lichen planus (LP)
Beyond the preview
Go deeper on NCT05188521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05188521.